Neonatal fecal abundance of *Bifidobacterium longum* subspecies *infantis* is not associated with anthropometric outcomes up to 6 months of age in Bangladeshi infants

Cole K. Heasley[1], Veselina Stefanova[1], Celine Funk[1], Aline C. Freitas[1], Grace Li[1], Lisa G. Pell[1], Diego G. Bassani[1,2,3,4], Karen M. O'Callaghan[5], Prakesh S. Shah[2,6], Jakaria Shawon[7], S.M. Abdul Gaffar[7], Rashidul Haque[7], Shafiqul Alam Sarker[6], Daniel E. Roth[1,2,3,4*]

[1] Centre for Global Child Health, The Hospital for Sick Children, Toronto, Canada

[2] Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.

[3] Child Health Evaluative Sciences, Hospital for Sick Children, Toronto, Canada

[4] Department of Paediatrics, Hospital for Sick Children, Toronto, Canada

[5] Department of Nutritional Sciences, King's College London, London, United Kingdom

[6] Department of Pediatrics, Mount Sinai Hospital, Toronto, Canada

[7] Nutrition Research Division, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.

*Correspondence: Daniel Roth, daniel.roth@sickkids.ca, The Hospital for Sick Children, 555 University Ave, Toronto, Ontario, M5G 1X8, Canada.

Abstract

Background: *Bifidobacterium longum* subspecies *infantis* (*B. infantis*) abundance in the infant gut may be associated with growth and health outcomes. However, these relationships have not been widely studied in settings where *B. infantis* is a dominant early-life intestinal commensal bacteria and linear growth faltering is prevalent.

Objective: To estimate associations between neonatal fecal *B. infantis* abundance and infant anthropometric outcomes up to 6 months of age. Diarrhea and hospitalizations were examined as secondary morbidity outcomes.

Methods: We conducted a secondary analysis of data from an observational cohort of generally healthy infants in Dhaka, Bangladesh. *B. infantis* absolute abundance in stool was quantified by qPCR; for each infant (n=964), the mean abundance from 0 to 28 days of age was used as the primary exposure variable. Length-for-age, weight-for-age, and weight-for-length z-scores were derived at birth, 2, 3, and 6 months of age. Infant diarrheal and hospitalization outcomes were assessed from the end of 1 month to 2 and 6 months of age. Associations of mean *B. infantis* absolute abundance with infant outcomes were estimated using linear and modified Poisson regression, adjusted for selected sociodemographic and clinical characteristics.

Results: Mean neonatal fecal *B. infantis* abundance had a bimodal distribution, with most infants (63%) having detectable *B. infantis* by 28 days of age. Anthropometric z-score distributions were shifted down, with means below zero at all ages. Neonatal *B. infantis* absolute abundance was not associated with any anthropometric outcome at 2, 3, or 6 months of age ($p>0.05$ for all, n of

525-677), or with the risks of diarrheal events or hospitalizations ($p>0.05$ for both, n of 938 and 935, respectively).

Conclusions: The lack of association of neonatal *B. infantis* abundance with growth outcomes suggests that promotion of early *B. infantis* colonization would be unlikely to improve infant growth in populations with postnatal faltering.

Keywords: *Bifidobacterium longum* subspecies *infantis*, Anthropometry, Growth, Gastrointestinal microbiome, Microbiota, Infant health

57 ## Introduction

58 *Bifidobacterium longum* ssp. *infantis* (*B. infantis*) is an early-life colonizer of the infant gut that
59 is well adapted to metabolize human milk oligosaccharides (HMOs), a group of complex
60 indigestible sugars present in human milk (1, 2). HMO metabolism by *B. infantis* produces lactic
61 and acetic acids and other short-chain fatty acids that contribute to a lower pH in the gut lumen,
62 inhibit proliferation of potential pathogens, and may influence immunoregulation and immune
63 development (2-6). *B. infantis* colonization is hypothesized to improve infant health including
64 linear and ponderal growth outcomes, possibly by reducing the risk of common morbidities such
65 as diarrheal illness, and through effects of short-chain fatty acids on host metabolism including
66 gluconeogenesis (7).

67 However, there is a lack of epidemiological evidence in support of an effect of early postnatal *B.*
68 *infantis* colonization on infant growth. Few studies have been conducted in low- and middle-
69 income countries (LMICs); in one study of infants in Bangladesh, there was a positive
70 association between *B. infantis* and infant weight-for-age z-score (WAZ) and weight-for-length
71 z-score (WLZ) in the first year after birth (8), but in a multivariable-adjusted analysis of cohorts
72 in Bangladesh, Tanzania, and Pakistan, there were no associations between neonatal *B. infantis*
73 abundance and length-for-age z-score (LAZ) or WAZ at 24 months of age (9). A key
74 consideration in the interpretation of epidemiological studies is the wide global variation in *B.*
75 *infantis* abundance – in general, it is rare or even absent among infants in high-income countries
76 but frequently detected in LMICs (10-12), settings where infant growth faltering is most
77 common (13, 14). Therefore, while *B. infantis* abundance might be found to explain between-
78 individual variations in linear or ponderal growth within a study population, these associations
79 may not explain why nearly all infants in LMICs grow more slowly than expected for their
80 chronological age based on international growth standards (15).

81 In a cohort of generally healthy and mostly term-born infants in Dhaka, Bangladesh, we
82 previously found *B. infantis* was highly abundant in stool by 2 months of age and persisted to at
83 least 6 months of age; however, it was generally absent in the immediate postnatal period and
84 there was substantial variation in abundance in the first month (neonatal period) (16). To explore
85 the potential role of postnatal *B. infantis* colonization in modulating growth in early infancy, we
86 examined the associations between *B. infantis* abundance in the neonatal period and
87 anthropometric outcomes up to 6 months of age in the same cohort. In further analyses, we
88 estimated associations of *B. infantis* with stool pH and infant morbidity (diarrhea and
89 hospitalizations), considering that such relationships might represent pathways by which *B.*
90 *infantis* could influence infant growth.

91

92 # Methods

93 **Study design and participants**

94 This secondary-use study was based on data from the Synbiotics for the Early Prevention of
95 Severe Infections in Infants (SEPSiS) observational cohort study (ClinicalTrials.gov
96 ID**:** NCT04012190). Approval for the original data collection was provided by The Hospital for
97 Sick Children Research Ethics Board (REB# 1000063899) and the International Centre for
98 Diarrhoeal Disease Research, Bangladesh (icddr,b) Research Ethics Committee (PR-19045).
99 Approval for this secondary use study was obtained from The Hospital for Sick Children
100 (REB#1000082019). Further details on the design and implementation of the SEPSiS
101 observational cohort study have been described elsewhere (16, 17). Briefly, between November
102 2020 and February 2022, infants were enrolled at two government healthcare facilities in Dhaka,
103 Bangladesh: Maternal and Child Health Training Institute and the Mohammadpur Fertility

104 Services and Training Centre. Infants were eligible for enrolment if they were delivered at a
105 study hospital, age zero (day of birth) to 4 days old, orally feeding at the time of screening, and
106 their caregivers were planning to maintain residence in the study catchment area until the infant
107 reached at least 60 days of age. Infants were ineligible for enrolment if they weighed <1500 g at
108 birth, had a major congenital anomaly of the gastrointestinal tract, death or major surgery were
109 likely within the first week after birth, were on mechanical ventilation or cardiac support, were
110 receiving or prescribed parenteral antibiotics, were enrolled in an ongoing clinical trial involving
111 the administration of probiotics and/or prebiotics, resided in the same household as another
112 infant under 60 days of age (excluding twins), prenatal or postpartum/postnatal non-dietary
113 probiotic supplements were used by the infant's mother or provided directly to the infant,
114 multiple gestation of the mother exceeded two, or the mother was diagnosed with HIV infection
115 and/or history of receiving anti-retroviral drug(s) for a presumed HIV infection. For each model
116 assessed, this study included all SEPSiS observational cohort participants who had relevant data.

117

118 **Stool sample collection**

119 Study personnel collected infant stool samples using standardized procedures according to one of
120 three schedules (A, B, or C). Infants in schedules A and B had up to 11 routine stool samples
121 collected (days 0 or 1, 3 or 4, 6 or 7, 10, 14, 21, 28, 35, 60, 90, and 180), whereas infants in
122 schedule C only had up to 3 routine stool samples collected (on the day of enrollment and twice
123 more on randomly assigned visits up to day 60). Because schedules A and B used the same
124 sample collection schedules, and had similar numbers of samples per infant, and no other
125 differences in the protocol that would influence the current analysis, the groups were combined
126 for all analyses in this study. In hospital or the infant's home, stool samples were collected using

127 a wrapped plastic sheet or plastic wrap-lined diaper, then manually homogenized and aliquoted
128 into appropriate vials. For samples collected by study workers (all schedule A/B samples, 46% of
129 schedule C samples), aliquots intended for qPCR were placed in the vapour phase of liquid
130 nitrogen within 20 minutes of defecation, and aliquots for stool pH measurements were stored in
131 a cold box at 2-8ºC (never frozen). For schedule C samples that could not be collected directly
132 by study workers (54% of samples), the infant's caregiver was instructed to place the stool
133 sample in a cold box (maintained at 2-8ºC) within 20 minutes of defecation until it was
134 transported to the field office by study staff. All stool aliquots were placed into the vapour phase
135 of liquid nitrogen within 6 hours of defecation, before transport to icddr,b for storage at ≤-70ºC
136 until analysis.

137

138 **Sample processing and laboratory analyses**

139 Stool sample selection and quantification of *B. infantis* absolute abundance have been described
140 in detail elsewhere (16). Briefly, total DNA was extracted from 100-150 mg of stool using
141 QIAamp Fast DNA Stool Mini Kit (QIAGEN, Germany). Total DNA mass was quantified using
142 a Nanodrop 2000 spectrophotometer (Thermo Scientific, USA). *B. infantis* was quantified using
143 qPCR with primer-probes specific to *B. infantis* (18). Cell counts were based on standard curves
144 generated using pure cultures of *B. infantis* ATCC 15697, and absolute abundance was
145 normalized to total DNA mass and expressed as log *B. infantis* cells per µg total DNA. For
146 samples with undetectable *B. infantis* (*i.e.*, did not amplify or had cell counts below the limit of
147 detection of the qPCR assay), a value of 2.5 log cells/µg DNA was imputed for the absolute

148 abundance. This value corresponds to the median of half the limit of detection normalized to
149 each undetected sample DNA mass.

150 Aliquots for measuring stool pH were brought to room temperature before mixing 1 g of stool
151 with deionized water to achieve a total sample volume of 10 mL. Stool pH was measured twice
152 per sample using portable pH testers (Hanna, USA). If the difference between the two pH
153 measurements was greater than 0.5 pH units, a third measurement was taken, and the mean of the
154 two closest pH values was used in analyses.

155

156 **Clinical and anthropometric data collection**

157 Routine study visits were conducted five times at the infant's home or via phone call up to and
158 including 14 days of age, then weekly until 60 days, then at 3 and 6 months. Study staff collected
159 information about feeding practices (7-day recall), infant receipt of antibiotics (since last study
160 visit), diarrheal episodes, and hospital admissions (17). Diarrheal episodes were based on a
161 caregiver response of 'yes' when asked if the infant had diarrhea described as the "frequency of
162 stool is too often, the quantity of stool is too much, and/or the consistency is too loose compared
163 to the usual," since the prior study visit or in the preceding 7 days, including the day of the
164 encounter. Hospitalizations were verified and recorded by Study Medical Officers and were
165 defined on the basis of admission to hospital for any reason other than injury or elective surgery.

166 Anthropometric measurement methods were adapted from standardized procedures from the
167 INTERGROWTH-21st study (19). Trained study staff measured infant length and weight on the
168 day of enrolment and during scheduled home visits at 2, 3, and 6 months postnatal age. Length
169 was measured using a wooden length board to the nearest 1 mm (Shorr board, Weight and
170 Measure LLC, USA) and weight was measured with a Seca 334 or 354 digital scale to the

171 nearest 1 g (Seca, USA). Each measurement was obtained twice and averaged; if the difference
172 between two measurements was greater than 7 mm or 50 g for length and weight, respectively, a
173 third measurement was taken. If a third measurement was taken, the two closest measurements
174 were used to calculate the average.

175 For measurements on days 0-2 of age, baseline LAZ and WAZ were derived using
176 INTERGROWTH-21st Newborn Size growth curves (20). Beyond 2 days of age, including visits
177 at 2, 3, and 6 months postnatal age, the WHO Child Growth Standards were used to derive LAZ
178 and WAZ for term infants (gestational age ≥260 days) (21), whereas for preterm infants
179 (gestational age <260 days) older than 2 days postnatal age, LAZ and WAZ were generated
180 using the INTERGROWTH-21st Postnatal Growth for Preterm Infants growth curves (22). All
181 WLZs were derived from WHO Child Growth Standards as the index is independent of age. In
182 instances of implausible values (infant length or weight decreasing over time or LAZ/WAZ ≥±6
183 or WLZ ≥±5), values and trajectories were examined independently by two reviewers to
184 determine if any measurements should be removed. In total, individual growth trajectories for 92
185 (4.8%) infants were flagged for investigation and 58 (0.86%) discrete length or weight
186 measurements were removed from 56 infant trajectories (resulting in the exclusion of one full
187 infant trajectory). For each infant, anthropometric measurements were grouped according to the
188 following age intervals: baseline (days 0-4), 2 months (days 59-75), 3 months (days 76-110), and
189 6 months (days 160-200).

190

191 **Statistical analysis**

192 Baseline characteristics were described using medians (with 25th and 75th centiles) for continuous
193 data and counts (proportions) for categorical data. Scatterplots with LOESS curves were

194 generated for all *B. infantis*-anthropometric associations investigated to visualize trends in
195 bivariate relationships.

196 *B. infantis* absolute abundance in the first 28 days after birth was summarized at the infant level
197 using the mean of each infant's analyzed samples from 0-28 days (neonatal period). Mean
198 neonatal *B. infantis* absolute abundance refers to the measure of each infant's abundance level
199 averaged across all the infant's stool samples with qPCR abundance data from days 0-28.
200 Several summary measures of neonatal *B. infantis* absolute abundance were tested and the mean
201 was selected for primary analyses (see Supplementary Methods, **Table S1 and Figures S1-3**).
202 Associations between mean *B. infantis* absolute abundance and anthropometric indices at
203 specified time points were estimated using linear regression models. All models with
204 anthropometric outcomes included adjustment for the same anthropometric index measured at
205 baseline. Sample sizes for the otherwise unadjusted models included only those infants with
206 complete covariate data and who were included in the corresponding multivariable-adjusted
207 analysis. Additional covariates in the adjusted regression models included: breastfeeding status
208 assessed at or closest to age 28 days, infant sex, hospital enrolment site, mode of delivery,
209 gestational age at birth, neonatal infant systemic antibiotics (ever/never), maternal BMI at
210 enrolment, maternal education, maternal age, the number of infants within the household under 5
211 years of age, and household asset index quintile. Asset index was calculated for all infants
212 enrolled in the SEPSiS observational cohort and a related clinical trial (23) using principal
213 component analysis of a checklist of household assets and scored based on the first principal
214 component, which was then converted to quintiles. The primary outcome was LAZ and the
215 secondary outcomes were WAZ and WLZ.

216 In sensitivity analyses, we used the following alternative approaches to define neonatal *B.*
217 *infantis* abundance: 1) area under the curve (of absolute abundance by age, as a continuous

218 variable); 2) *B. infantis* absolute abundance expressed as a categorical dichotomous variable
219 defined as undetectable (all stool samples within the first 28 days of age with undetectable *B.*
220 *infantis*) or detectable (at least one stool sample with detectable *B. infantis* within the first 28
221 days of age). We also conducted analyses in which we altered the period during which *B. infantis*
222 mean abundance was summarized (0-14 or 0-60 days of age). We also conducted a cross-
223 sectional analysis using the single absolute abundance measurement that was closest in time to
224 the 2-month anthropometric measurement (and collected within the interval of 59-75 days). We
225 repeated the primary analysis in a subset of the cohort restricted to infants assigned to specimen
226 collection schedules A/B. Lastly, we estimated the association between baseline anthropometric
227 indices and neonatal *B. infantis* abundance as the outcome, and we performed the primary
228 analyses without adjustment for the baseline measures.

229 Associations between median neonatal stool pH and LAZ, WAZ, and WLZ at 2, 3, and 6 months
230 were assessed using linear regression models with the same covariates as described above. In a
231 sensitivity analysis, we conducted a cross-sectional analysis by using the pH measurement
232 closest in time to each anthropometric measurement (and within the same age interval used for
233 the corresponding anthropometric value). We used linear mixed effects regression models to
234 estimate the association between *B. infantis* absolute abundance and stool pH (corresponding
235 values generated for the same stool sample), using all samples collected in the neonatal period.
236 The mean stool pH of samples with detectable versus undetectable *B. infantis* was compared
237 using the Kruskal-Wallis test.

238 To estimate associations of mean neonatal *B. infantis* abundance with diarrheal events from 29 to
239 60 days (2 months) of age and hospitalizations (excluding trauma/injury or elective surgeries)
240 from 29 to 180 days (6 months) of age, infants were categorized as never/ever having had a
241 diarrheal event or hospitalization during the defined period. Modified Poisson regression models

242 (with robust standard errors) were used to estimate relative risks of diarrhea and hospitalization
243 by mean neonatal *B. infantis* abundance. In adjusted models, covariates included breastfeeding
244 status assessed on or closest to 28 days of age, mode of delivery, gestational age, neonatal
245 antibiotic exposure, maternal education, and household asset index quintile.

246 We considered the use of path analysis to examine if any associations between *B. infantis*
247 abundance and anthropometric indices could be explained by mediating roles of stool pH or
248 clinical events, but these analyses were not pursued due to null associations of *B. infantis*
249 abundance with anthropometric indices.

250 The Holm method was used to account for multiple comparisons and maintain an overall α of
251 0.05 for each set of analyses (one set refers to all analyses presented within each table). All
252 analyses were conducted using R statistical software (Version 4.4.1) (24). All statistical code
253 used in analyses for this study was independently reviewed by a second data analyst.

254 ## Results

255 Of 1939 infants enrolled in the SEPSiS observational cohort, 964 infants (50%) had at least one
256 neonatal *B. infantis* absolute abundance measurement and at least one eligible anthropometric
257 measure (**Figure 1**). Infants were predominantly born full-term (92%), via c-section (52%), and
258 68% were exclusively breastfed up to 28 days of age (**Table 1, Table S2** stratified by infant sex).
259 Of the 3903 stool samples collected in the neonatal period, 2982 (76%) underwent qPCR testing.
260 From 0-28 days of age, infants assigned to schedules A/B and C contributed a median (25th, 75th
261 centiles) of 6.0 (2.0, 7.0) and 1.0 (1.0, 3.0) stool samples for qPCR analysis, respectively. There
262 were 1164 infants (60%) with at least one neonatal stool pH measurement and at least one
263 anthropometric measurement in one of the age intervals assessed. There were 935 infants (48%)
264 with a neonatal *B. infantis* abundance measurement who also had available morbidity-related
265 data up to 6 months of age.

266 The distribution of mean neonatal *B. infantis* absolute abundances was bimodal, with a median
267 (25th,75th percentiles) of 3.7 log cells/µg DNA (2.5, 7.6) (**Figure 2**). When the age range was
268 reduced to 0-14 days, the median reduced to 2.9 (2.5, 6.9) log cells/µg DNA and when expanded
269 to 0-60 days, the median abundance increased to 5.0 (2.5, 7.7) log cells/µg DNA. Among the 966
270 infants with at least one neonatal qPCR measurement from 0-28 days of age, 608 had *B.*
271 *infantis* detected in at least one stool sample (63%) and had a median (25th, 75th) of their mean
272 neonatal abundance values of 6.6 log cells/µg DNA (2.6, 8.9); among infants with
273 undetectable *B. infantis* in all stool samples from 0-28 days of age (37%), the mean neonatal
274 abundance values were all uniformly 2.5 log cells/µg DNA (corresponding to the imputed lower
275 limit of quantification). The mean (SD) value of infant-level median stool pH values was 5.7
276 (0.6).

277 Anthropometric z-scores were approximately normally distributed but shifted downwards such
278 that all means were below zero at all timepoints (**Figure 2** and **Table S3**). Infants included in this
279 sub-study were generally representative of the overall SEPSiS observational cohort with respect
280 to growth patterns (**Table S3**).



Figure 1. Study flow diagram showing the number of infants from the SEPSiS observational study cohort who contributed to the primary and secondary analyses in this study. Bold lines indicated pathway to primary analysis sample (shown in dashed lines). [a] Complete covariates include: enrolment site, infant sex, breastfeeding status at 28 days of age (if available) or at age most proximal to 28 days, mode of delivery, gestational age at birth, infant antibiotic exposure by 28 days of age, maternal BMI, maternal education, maternal age, number of infants within the household under 5 years of age, and household asset index quintile.

290 **Table 1.** Baseline characteristics of infants with a mean *B. infantis* abundance value and at least
291 one anthropometric measure.

Characteristic	**Median (25th, 75th centiles) or count (%) (n=964)**
Enrolment site	
Mohammadpur Fertility Services and Training Centre	574 (60)
Maternal and Child Health Training Institute	390 (40)
Sex	
Male	467 (48)
Female	497 (52)
Baseline LAZ [a, b]	-0.84 (-1.5, -0.17)
Baseline WAZ [a, b]	-0.88 (-1.6, -0.21)
Baseline WLZ [a, b]	-0.61 (-1.4, 0.17)
Mode of delivery	
Vaginal	463 (48)
C-section	501 (52)
Stool collection schedule [c]	
A/B	360 (37)
C	604 (63)
Breastfeeding status by 28 days of age	
Exclusively breastfed	660 (68)
Predominantly breastfed	174 (18)
Partially breastfed or not breastfed	130 (13)
Gestational age at birth [a]	
Term (≥ 260 days)	884 (92)
Preterm (<260 days)	76 (7.9)
Antibiotic use by 28 days of age	
Yes	104 (11)
No	860 (89)
Maternal BMI (kg/m^2) [a]	26 (23, 29)
Maternal education	
Little to no schooling [d]	272 (28)
Secondary incomplete	335 (35)
Secondary complete or higher	357 (37)
Maternal age (years)	24 (20, 28)
Infants within the household under 5 years of age [a]	0 (0, 1)
Household asset index quintile [a, e]	
1 (lowest wealth)	176 (18)
2	195 (20)
3	198 (21)
4	199 (21)
5 (highest wealth)	185 (19)
Stool *B. infantis* absolute abundance measurements per infant, 0-28 days of age	
Infants with 1 sample	420 (44)

Infants with 2-4 samples	221 (23)
Infants with 5-7 samples	323 (34)

Abbreviations: BMI, body mass index; LAZ, length-for-age z-score; WAZ, weight-for-age z-score; WLZ, weight-for-length z-score; qPCR, quantitative polymerase chain reaction.

[a] n < 964: baseline LAZ, n=930; baseline WAZ, n=924; baseline WLZ, n=880; gestational age at birth, n=960; maternal BMI, n=925; number of infants within household under 5 years of age, n=948; asset index, n=953.

[b] Mean and SD of anthropometric z-score distributions are shown in Table S3.

[c] Infants in schedule A/B had up to 7 routine stool samples collected in the first month of age (days 0 or 1, 3 or 4, 6 or 7, 10, 14, 21, and 28). Infants in schedule C had up to 3 routine stool samples collected (day of enrolment and twice more on randomly assigned visits up to 60 days of age).

[d] Little to no schooling was defined as: no schooling at all; having completed *qawmi madrasa* but no other schooling; or, up to 5 years of schooling or *alia madrasa*.

[e] Quintiles of a score derived by first component of principal component analysis from a checklist of household assets from all SEPSiS infants (observational cohort and associated trial). Higher quintile relates to ownership of more assets.



Figure 2. Distributions of anthropometric indices, mean *B. infantis* abundance, and median stool pH. Kernel density plots for infants with at least one *B. infantis* qPCR measurement and complete covariates of A) LAZ (Baseline, n=894; 2 months, n=652; 3 months, n=677; 6 months, n=560), B) WAZ (Baseline, n=888; 2 months, n=649; 3 months, n=677; 6 months, n=562), and C) WLZ (Baseline, n=838; 2 months, n=609; 3 months, n=634; 6 months, n=525). Standard normal distributions (mean=0, SD=1) are shown as solid black lines in each panel. Histograms of D) mean neonatal *B. infantis* absolute abundance (n=964) and E) median neonatal stool pH (n=1238). Abbreviations: LAZ, length-for-age z-score; WAZ, weight-for-age z-score; WLZ, weight-for-length z-score.

318 There were no associations between mean neonatal *B. infantis* absolute abundance and LAZ,
319 WAZ, or WLZ, at 2, 3, or 6 months of age, in unadjusted or adjusted models (**Table 2**; **Figure**
320 **S4**). Neonatal *B. infantis* absolute abundance was not associated with baseline LAZ, WAZ, or
321 WLZ (**Table S4**). Inferences remained unchanged when participants were stratified by sex
322 (**Table S5)**, and in sensitivity analyses (**Tables S6-11**) with these exceptions: in the analysis
323 restricted to infants enrolled in schedules A/B, there was a significant positive association of
324 mean neonatal *B. infantis* with LAZ at 3 months of age and a significant negative association of
325 *B. infantis* with WLZ at 2 months of age, but both associations were attenuated to the null and no
326 longer significant at 6 months of age (**Table S12**). To investigate if the higher number of
327 samples in schedule A/B may have influenced the associations, the analysis was rerun using two
328 random samples per infant to resemble total sample numbers in schedule C, with selection
329 simulated 1000 times. Based on this further analysis, we did not find evidence that the greater
330 number of stool samples per infant in schedules A/B during the 0-28 day period explained the
331 discrepancy in findings between the sub-analysis of schedule A/B and the primary analysis
332 (**Table S13**).

333 **Table 2.** Associations of mean *B. infantis* absolute abundance (0-28 days of age) and infant
334 anthropometric indices at 2, 3, and 6 months of age.

Outcome, Infant age	**Unadjusted model[a]**			**Adjusted model[b]**		
	n	Difference in anthropometric z-score (95% CI) for each 1 log cell/µg DNA increase in mean *B. infantis* absolute abundance	p-value	n	Difference in anthropometric z-score (95% CI) for each 1 log cell/µg DNA increase in mean *B. infantis* absolute abundance	p-value
LAZ						
2 months	652	-0.014 (-0.041, 0.014)	0.3	652	-0.0013 (-0.027, 0.025)	>0.9
3 months	677	0.011 (-0.016, 0.038)	0.4	677	0.022 (-0.0043, 0.049)	0.1
6 months	560	-0.011 (-0.041, 0.018)	0.5	560	0.0080 (-0.022, 0.038)	0.6
WAZ						
2 months	649	-0.012 (-0.038, 0.014)	0.4	649	-0.0032 (-0.029, 0.023)	0.8
3 months	677	0.0035 (-0.023, 0.030)	0.8	677	0.012 (-0.015, 0.040)	0.4
6 months	562	0.0023 (-0.030, 0.034)	0.9	562	0.0093 (-0.024, 0.043)	0.6
WLZ						
2 months	609	0.0065 (-0.030, 0.043)	0.7	609	-0.0096 (-0.048, 0.029)	0.6
3 months	634	-0.0097 (-0.042, 0.023)	0.6	634	-0.020 (-0.055, 0.015)	0.3
6 months	525	0.0024 (-0.036, 0.041)	>0.9	525	-0.016 (-0.056, 0.025)	0.4

335 Abbreviations: CI, confidence interval; LAZ, length-for-age z-score; WAZ, weight-for-age z-score; WLZ,
336 weight-for-length z-score.
337 [a] Baseline measurement (on day of enrolment) of the same parameter as the outcome was included as a
338 covariate in all linear regression models.
339 [b] Additional covariates in adjusted models: enrolment site, infant sex, breastfeeding status at 28 days of
340 age (if available) or at age most proximal to 28 days, mode of delivery, gestational age at birth, infant
341 antibiotic exposure by 28 days of age, maternal BMI, maternal education, maternal age, number of infants
342 within the household under 5 years of age, and household asset index quintile.

343

344 In all individual neonatal stool samples (n=2118 samples), there was a 0.093 (95% CI: 0.084,
345 0.10; p <0.001) decrease in stool pH per one unit increase in log *B. infantis* cells/µg of DNA.
346 There was evidence that the relationship between *B. infantis* absolute abundance with stool pH
347 may be non-linear (**Figure S5**). When *B. infantis* abundance was dichotomized, the mean pH of
348 stool samples (SD) with detectable and undetectable *B. infantis* was 5.5 (0.68) and 6.0 (0.54),
349 respectively (p <0.001). Median stool pH up to 28 days after birth was significantly associated
350 with WAZ at 2 months and WLZ at 2 and 3 months of age in unadjusted models (**Table 3** and
351 **Figure S6**), but only the association with WAZ at 3 months remained statistically significant
352 after covariate adjustment (Table 3). There was no association between stool pH and LAZ at any
353 timepoint (**Table 3**). Stool pH was not associated with any anthropometric indices in cross-
354 sectional analyses, which used the stool pH value for the sample collected closest in time to the
355 anthropometric measurement (**Table S14**).

356 Of the infants who had available *B. infantis* absolute abundance data and had not exited the study
357 by the end of 2 or 6 months, 36 (3.8%) infants had at least one diarrheal event between 29 and 60
358 days of age (n=938), and 78 (8.3%) had at least one hospitalization event between 29 and 180
359 days of age (n=935). Mean *B. infantis* absolute abundance was not associated with the risk of an
360 infant experiencing a diarrheal event (RR = 0.96 (95%CI: 0.82, 1.1) per 1 log *B. infantis* cells/µg
361 of DNA increase; p = 0.5) or hospitalization (RR = 1.0 (95%CI: 0.90, 1.1) per 1 log *B. infantis*
362 cells/µg of DNA increase; p>0.9).

363

364

365

366

367 **Table 3.** Associations of median neonatal stool pH (0-28 days of age) and infant anthropometric
368 indices at 2, 3, and 6 months of age.

Outcome, Infant age	Unadjusted model [a]			Adjusted model [b]		
	n	Difference in growth outcome per 1 unit decrease in pH (95% CI)	p-value	n	Difference in growth outcome per 1 unit decrease in pH (95% CI)	p-value
LAZ						
2 months	854	-0.017 (-0.11, 0.078)	0.7	854	0.014 (-0.079, 0.11)	0.8
3 months	843	0.024 (-0.073, 0.12)	0.6	843	0.060 (-0.039, 0.16)	0.2
6 months	695	-0.062 (-0.18, 0.053)	0.3	695	-0.0039 (-0.13, 0.12)	>0.9
WAZ						
2 months	853	0.12 (0.028, 0.21)	0.01[c]	853	0.088 (-0.0062, 0.18)	0.07
3 months	842	0.17 (0.073, 0.26)	<0.001[d]	842	0.15 (0.049, 0.25)	0.004[d]
6 months	698	0.11 (-0.016, 0.23)	0.09	698	0.090 (-0.041, 0.22)	0.2
WLZ						
2 months	812	0.19 (0.067, 0.31)	0.002[d]	812	0.094 (-0.040, 0.23)	0.2
3 months	796	0.18 (0.070, 0.30)	0.002[d]	796	0.11 (-0.010, 0.24)	0.07
6 months	659	0.17 (0.030, 0.31)	0.02[c]	659	0.092 (-0.060, 0.24)	0.2

369 Abbreviations: CI, confidence interval; LAZ, length-for-age z-score; WAZ, weight-for-age z-score; WLZ,
370 weight-for-length z-score.
371 [a] Baseline measurement (on day of enrolment) of the same parameter as the outcome was included as a
372 covariate in all linear regression models.
373 [b] Additional covariates in adjusted models: enrolment site, infant sex, breastfeeding status at 28 days of
374 age (if available) or at age most proximal to 28 days of age, mode of delivery, gestational age at birth,
375 infant antibiotic exposure by 28 days of age, maternal BMI, maternal education, maternal age, number of
376 infants within the household under 5 years of age, and household asset index quintile.
377 [c] No longer statistically significant after Holm's adjustment.
378 [d] Remained statistically significant after Holm's adjustment.
379
380
381

382 ## Discussion

383 In a cohort of generally healthy infants in Dhaka, Bangladesh, *B. infantis* stool absolute
384 abundance in the neonatal period was not associated with anthropometric indices up to 6 months
385 of age. As expected, stool pH was inversely associated with stool *B. infantis* abundance (2) but
386 we did not corroborate prior findings of an inverse association between stool pH and LAZ (25).
387 Although there was an inverse association of stool pH with infant WAZ in early infancy, the
388 magnitude of the association was small (~0.1 SD per 1 unit change in stool pH), especially given
389 the narrow range of observed pH values. Additionally, this relationship could not be explained
390 by the pH-lowering effect of *B. infantis*; therefore, if the relationship between stool pH and
391 weight represents a causal pathway, it may be attributable to other components of the
392 microbiome, or it may be confounded by unmeasured aspects of the diet or medications that
393 influence both stool pH and weight gain (26).

394 The null associations between *B. infantis* abundance and anthropometric indices in the first 6
395 months postnatal age were broadly consistent with a prior study that did not find relationships
396 between neonatal *B. infantis* abundance and LAZ (n=292) or WAZ (n=472) at 24 months of age
397 in Bangladesh, Pakistan, and Tanzania (9). In the Bangladeshi and Tanzanian cohorts, there was
398 a positive association of enrolment (*i.e.*, birth) LAZ with *B. infantis* abundance (9), which raises
399 the possibility of reverse causality. However, we did not observe a similar association in the
400 SEPSiS observational cohort, and our inferences were the same in models with and without
401 adjustment for baseline LAZ.

402 Recent systematic reviews of the effects of probiotics in infants have included few studies of *B.*
403 *infantis*, or when included, were generally administered in combination with other probiotic
404 species (27-29), or have focused on *B. infantis* but did not address growth outcomes (30). Two

405 trials of the *B. infantis* probiotic EVC001 conducted in the United States did not find effects on
406 achieved weight/weight gain or length among term exclusively breastfed infants (31) or preterm
407 infants (32). Similarly, two trials in Spain showed no effects of *B. infantis* probiotics on infant
408 weight or length (33, 34). However, in a single-blind randomized controlled trial involving 2- to
409 6-month old infants with severe acute malnutrition in Dhaka, Bangladesh (n= 67), infants treated
410 with *B. infantis* EVC001 daily for 28 days had a significantly higher WAZ and mid-upper arm
411 circumference compared to the placebo group at 28 days post-intervention, despite no effect on
412 LAZ (35, 36). Some studies of probiotics with multiple species including *B. infantis* reported
413 positive effects on weight gain in very preterm infants in Australia and New Zealand (37) or very
414 low birth weight infants in the United States (38) and Germany (39), but it is uncertain whether
415 the effects were specifically attributable to *B. infantis*. In a sensitivity analysis in the present
416 study, which was restricted to a subset of infants who had stool sampled more frequently
417 (schedule A/B; 40-42% of infants in primary analyses), *B. infantis* was positively associated with
418 LAZ and negatively associated with WLZ at 3 months of age but these associations were
419 substantially attenuated by 6 months of age and were not explained by a greater precision of *B.*
420 *infantis* abundance measurement due to higher sample numbers. Therefore, we did not consider
421 these findings to have altered the overall conclusion that neonatal *B. infantis* abundance is
422 unrelated to growth in the first 6 months postnatal age.

423 A meta-analysis of trials investigating the effect of probiotics containing *B. infantis* on preterm
424 and/or very low birth weight infants found that administering probiotics reduced all-cause
425 mortality (14 trials with 4292 infants), necrotizing enterocolitis (15 trials with 3626 infants), and
426 late onset sepsis (13 trials with 4123 infants) (30). However, only 5 of the 16 studies included
427 100 or more infants in each trial arm and all studies used a combination of probiotics that
428 included *B. infantis*, rather than *B. infantis* alone. In the present study, we did not find

429 associations between *B. infantis* neonatal abundance and either diarrheal events or
430 hospitalizations; however, we acknowledge that these analyses may have been underpowered
431 due to a low number of events. We did not assess associations with cause-specific
432 hospitalizations due to the low number of events related to discrete causes. However, we
433 acknowledge that the use of all-cause hospitalization as the outcome measure may have biased
434 the association towards the null if there were only certain morbidities for which there were true
435 associations with *B. infantis* abundance.

436 Examining individual-level risk factors, such as *B. infantis* abundance, may identify sources of
437 inter-individual variations in growth within a population; however, inter-individual variations
438 may not provide insights into a population-level phenomenon (15, 40). Growth faltering in
439 LMICs is not restricted to a subset of infants with stunting within a population, but rather the
440 whole population distributions of anthropometric indices are shifted downwards (14, 15). Given
441 the high prevalence of *B. infantis* colonization in populations with endemic postnatal growth
442 faltering (10-12), and the absence of associations of *B. infantis* with growth at the infant level as
443 observed here, there is unlikely to be an important role for early postnatal *B. infantis* colonization
444 in mitigating growth-faltering in such settings.

445 Several limitations of the present study should be considered. Stool *B. infantis* abundance was
446 used as a proxy of intestinal *B. infantis* abundance but may not reflect variability in abundance
447 within the intestine (41); however, methods for obtaining luminal samples from infants'
448 intestinal tracts rely on procedures that would be invasive, infeasible and unethical in a large
449 cohort study in this age group. We focused our analysis on *B. infantis* colonization in the
450 neonatal period because most infants were eventually colonized with *B. infantis* by 1-2 months
451 of age (16); therefore, we were unable to examine the effects of longer-term colonization.
452 Additionally, we only explored the associations between infant growth and the abundance of

453 naturally occurring *B. infantis* without consideration of strain-level distinctions. Beneficial
454 effects from commensals or probiotics may be strain-specific; for example, HMO gene clusters
455 are highly conserved across *B. infantis* strains, but the presence of specific genes within clusters
456 differ among *B. infantis* strains (12, 42, 43). The study population had a high C-section rate,
457 which influences early gut microbial succession patterns (16); however, this rate of C-section is
458 comparable to other studies in this setting (35, 44).

459 **Conclusion**

460 Stool absolute abundance of *B. infantis* in the first month after birth was not associated with
461 linear or ponderal growth up to 6 months of age in generally healthy infants in Dhaka,
462 Bangladesh. Based on these findings, promotion of early *B. infantis* colonization through
463 interventions such as *B. infantis* probiotic administration in the neonatal period may not be
464 expected to improve growth outcomes in generally healthy infants born in settings with high
465 prevalence of natural *B. infantis* colonization and where postnatal faltering is widespread.

466 **Author contributions**

467 Conceptualization or design of the work (CKH, DER, KMOC, LGP, DGB, PS, SS, VS); Data
468 generation/ collection (ACF, AG, GL, JS, RH, SS); Supervision of field or lab activities (AG,
469 RH, SS); Analysis of data (CKH, CF); Supervision of data analysis (DER); Writing manuscript
470 (CKH, VS); Revising manuscript critically (ACF, AG, CF, DER, GL, JS, KMOC, LGP, DGB,
471 PS, SS, VS).

472 **Acknowledgements**

473 We would like to thank the families who participated in the SEPSiS cohort study, as well as the
474 other SEPSiS project co-investigators and study personnel who were involved in data collection
475 and laboratory analysis.

476 **Funding**

477 This research was funded by The Bill and Melinda Gates Foundation, grant number INV-007389
478 to The Hospital for Sick Children and grant GR-02268 to the International Centre for Diarrhoeal
479 Disease Research, Bangladesh (icddr,b). The funders had no role in the study design, data
480 collection, statistical analysis, preparation of the manuscript, or the decision to submit the
481 manuscript for publication.

482 **Data availability**

483 All data and code used for the analyses are available on Borealis:
484 https://doi.org/10.5683/SP3/PWPMGK

485 **Conflict of interest**

486 The authors report no conflict of interest.

References

1. Underwood MA, German JB, Lebrilla CB, Mills DA. Bifidobacterium longum subspecies infantis: champion colonizer of the infant gut. Pediatr Res. 2015;77(1-2):229-35, doi:10.1038/pr.2014.156.
2. Frese SA, Hutton AA, Contreras LN, Shaw CA, Palumbo MC, Casaburi G, et al. Persistence of Supplemented Bifidobacterium longum subsp. infantis EVC001 in Breastfed Infants. mSphere. 2017;2(6), doi:10.1128/msphere.00501-17.
3. Henrick BM, Rodriguez L, Lakshmikanth T, Pou C, Henckel E, Arzoomand A, et al. Bifidobacteria-mediated immune system imprinting early in life. Cell. 2021;184(15):3884-98.e11, doi:10.1016/j.cell.2021.05.030.
4. Huda MN, Ahmad SM, Alam MJ, Khanam A, Kalanetra KM, Taft DH, et al. Bifidobacterium Abundance in Early Infancy and Vaccine Response at 2 Years of Age. Pediatrics. 2019;143(2), doi:10.1542/peds.2018-1489.
5. Laursen MF, Sakanaka M, Von Burg N, Mörbe U, Andersen D, Moll JM, et al. Bifidobacterium species associated with breastfeeding produce aromatic lactic acids in the infant gut. Nature Microbiology. 2021;6(11):1367-82, doi:10.1038/s41564-021-00970-4.
6. Fukuda S, Toh H, Hase K, Oshima K, Nakanishi Y, Yoshimura K, et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature. 2011;469(7331):543-7, doi:10.1038/nature09646.
7. Boets E, Gomand SV, Deroover L, Preston T, Vermeulen K, De Preter V, et al. Systemic availability and metabolism of colonic-derived short-chain fatty acids in healthy subjects: a stable isotope study. The Journal of Physiology. 2017;595(2):541-55, doi:10.1113/jp272613.
8. Vatanen T, Ang QY, Siegwald L, Sarker SA, Le Roy CI, Duboux S, et al. A distinct clade of Bifidobacterium longum in the gut of Bangladeshi children thrives during weaning. Cell. 2022;185(23):4280-97 e12, doi:10.1016/j.cell.2022.10.011.
9. Colston JM, Taniuchi M, Ahmed T, Ferdousi T, Kabir F, Mduma E, et al. Intestinal Colonization With Bifidobacterium longum Subspecies Is Associated With Length at Birth, Exclusive Breastfeeding, and Decreased Risk of Enteric Virus Infections, but Not With Histo-Blood Group Antigens, Oral Vaccine Response or Later Growth in T. Frontiers in Pediatrics. 2022;10, doi:10.3389/fped.2022.804798.
10. Taft DH, Lewis ZT, Nguyen N, Ho S, Masarweh C, Dunne-Castagna V, et al. Bifidobacterium Species Colonization in Infancy: A Global Cross-Sectional Comparison by Population History of Breastfeeding. Nutrients. 2022;14(7):1423, doi:10.3390/nu14071423.
11. Lawley B, Otal A, Moloney-Geany K, Diana A, Houghton L, Heath A-LM, et al. Fecal Microbiotas of Indonesian and New Zealand Children Differ in Complexity and Bifidobacterial Taxa during the First Year of Life. Applied and Environmental Microbiology. 2019;85(19), doi:10.1128/aem.01105-19.
12. Shao Y, Wang S, Gichuki BM, Stares MD, Rozday T, Kumar N, et al. Genomic Atlas of Early Life Bifidobacteria for Rational Development of Next-Generation Probiotics for Infant Health. Sneak Peak2025.
13. UNICEF, WHO, The World Bank. Levels and trends in child malnutrition: UNICEF / WHO / World Bank Group Joint Child Malnutrition Estimates: Key findings of the 2023 edition. New York: UNICEF and WHO; 2023.
14. Victora CG, Christian P, Vidaletti LP, Gatica-Domínguez G, Menon P, Black RE. Revisiting maternal and child undernutrition in low-income and middle-income countries: variable progress towards an unfinished agenda. The Lancet. 2021;397(10282), doi:10.1016/S0140-6736(21)00394-9.
15. Roth DE, Krishna A, Leung M, Shi J, Bassani DG, Barros AJD. Early childhood linear growth faltering in low-income and middle-income countries as a whole-population condition:

537 analysis of 179 Demographic and Health Surveys from 64 countries (1993-2015). Lancet Glob
538 Health. 2017;5(12):e1249-e57, doi:10.1016/S2214-109X(17)30418-7.
539 16. Freitas AC, Li G, Shawon J, Qamar H, Pell LG, Kabir M, et al. Abundance of
540 *Bifidobacterium* species in the infant gut microbiota and associations with maternal-infant
541 characteristics in Dhaka, Bangladesh. 2025.
542 17. Fung A, Heasley C, Pell LG, Bassani DG, Shah PS, Morris SK, et al. Severe infection
543 among young infants in Dhaka, Bangladesh: effect of case definition on incidence estimates.
544 2024.
545 18. Lawley B, Munro K, Hughes A, Hodgkinson AJ, Prosser CG, Lowry D, et al.
546 Differentiation of *Bifidobacterium longum* subspecies *longum* and *infantis* by quantitative PCR
547 using functional gene targets. PeerJ. 2017;5:e3375, doi:10.7717/peerj.3375.
548 19. Cheikh Ismail L, Knight H, Bhutta Z, Chumlea W. Anthropometric protocols for the
549 construction of new international fetal and newborn growth standards: the INTERGROWTH-21st
550 Project. BJOG: An International Journal of Obstetrics & Gynaecology. 2013;120(s2):42-7,
551 doi:10.1111/1471-0528.12125.
552 20. The International Fetal and Newborn Growth Consortium for the 21st Century.
553 INTERGROWTH-21st Newborn Size 2024 [Available from: https://intergrowth21.com/tools-
554 resources/newborn-size.
555 21. WHO. WHO child growth standards: length/height-for-age, weight-for-age, weight-for-
556 length, weight-for-height and body mass index-for-age: methods and development. Geneva:
557 WHO; 2006.
558 22. The International Fetal and Newborn Growth Consortium for the 21st Century.
559 INTERGROWTH-21st Postnatal Growth of Preterm Infants 2024 [Available from:
560 https://intergrowth21.com/tools-resources/postnatal-growth-preterm-infants.
561 23. Pell LG, Qamar H, Bassani DG, Heasley C, Funk C, Chen CY, et al. Neonatal
562 administration of Lactiplantibacillus plantarum ATCC 202195 with or without
563 fructooligosaccharide in Bangladesh: a placebo-controlled randomized trial. mSphere.
564 2025;10(3):e0103224, doi:10.1128/msphere.01032-24.
565 24. R Core Team. R: A Language and Environment for Statistical Computing. R Foundation
566 for Statistical Computing, Vienna, Austria; 2024.
567 25. Hossain MS, Das S, Gazi MA, Alam MA, Haque NMS, Mahfuz M, et al. Association of
568 faecal pH with childhood stunting: Results from a cross-sectional study. BMJ Paediatrics Open.
569 2019;3(1):e000549, doi:10.1136/bmjpo-2019-000549.
570 26. Yamamura R, Inoue KY, Nishino K, Yamasaki S. Intestinal and fecal pH in human health.
571 Frontiers in Microbiomes. 2023;2, doi:10.3389/frmbi.2023.1192316.
572 27. Panchal H, Athalye-Jape G, Rao S, Patole S. Growth and neuro-developmental
573 outcomes of probiotic supplemented preterm infants-a systematic review and meta-analysis.
574 Eur J Clin Nutr. 2023;77(9):855-71, doi:10.1038/s41430-023-01270-2.
575 28. Catania J, Pandit NG, Ehrlich JM, Zaman M, Stone E, Franceschi C, et al. Probiotic
576 Supplementation for Promotion of Growth in Children: A Systematic Review and Meta-Analysis.
577 Nutrients. 2021;14(1), doi:10.3390/nu14010083.
578 29. Guo H, Fan M, Hou T, Li Y, Wang S, Wang X, et al. Efficacy and Safety of
579 Bifidobacterium longum Supplementation in Infants: A Meta-Analysis of Randomized Controlled
580 Trials. Foods 2023, Vol 12, Page 4451. 2023-12-12;12(24), doi:10.3390/foods12244451.
581 30. Batta VK, Rao SC, Patole SK, Batta VK, Rao SC, Patole SK. Bifidobacterium infantis as
582 a probiotic in preterm infants: a systematic review and meta-analysis. Pediatric Research 2023
583 94:6. 2023;94(6), doi:10.1038/s41390-023-02716-w.
584 31. Smilowitz JT, Moya J, Breck MA, Cook C, Fineberg A, Angkustsiri K, et al. Safety and
585 tolerability of Bifidobacterium longum subspecies infantis EVC001 supplementation in healthy
586 term breastfed infants: a phase I clinical trial. BMC Pediatrics. 2017;17(1), doi:10.1186/s12887-
587 017-0886-9.

588 32. Bajorek S, Duar RM, Corrigan M, Matrone C, Winn KA, Norman S, et al. B. infantis
589 EVC001 Is Well-Tolerated and Improves Human Milk Oligosaccharide Utilization in Preterm
590 Infants in the Neonatal Intensive Care Unit. Frontiers in Pediatrics. 2022;9,
591 doi:10.3389/fped.2021.795970.
592 33. Manzano S, De Andrés J, Castro I, Rodríguez JM, Jiménez E, Espinosa-Martos I. Safety
593 and tolerance of three probiotic strains in healthy infants: a multi-centre randomized, double-
594 blind, placebo-controlled trial. Beneficial Microbes. 2017;8(4):569-78,
595 doi:10.3920/bm2017.0009.
596 34. Escribano J, Ferré N, Gispert-Llaurado M, Luque V, Rubio-Torrents C, Zaragoza-
597 Jordana M, et al. Bifidobacterium longum subsp infantis CECT7210-supplemented formula
598 reduces diarrhea in healthy infants: a randomized controlled trial. Pediatric Research.
599 2018;83(6):1120-8, doi:10.1038/pr.2018.34.
600 35. Nuzhat S, Hasan SMT, Palit P, Islam MR, Mahfuz M, Islam MM, et al. Effects of probiotic
601 and synbiotic supplementation on ponderal and linear growth in severely malnourished young
602 infants in a randomized clinical trial. Scientific Reports. 2023;13(1), doi:10.1038/s41598-023-
603 29095-w.
604 36. Barratt MJ, Nuzhat S, Ahsan K, Frese SA, Arzamasov AA, Sarker SA, et al.
605 Bifidobacterium infantis treatment promotes weight gain in Bangladeshi infants with severe
606 acute malnutrition. Science Translational Medicine. 2022-04-13;14(640),
607 doi:10.1126/scitranslmed.abk1107.
608 37. Jacobs SE, Group ftPS, Tobin JM, Group ftPS, Opie GF, Group ftPS, et al. Probiotic
609 Effects on Late-onset Sepsis in Very Preterm Infants: A Randomized Controlled Trial. Pediatrics.
610 2013/12/01;132(6), doi:10.1542/peds.2013-1339.
611 38. Al-Hosni M, Duenas M, Hawk M, Stewart LA, Borghese RA, Cahoon M, et al. Probiotics-
612 supplemented feeding in extremely low-birth-weight infants. J Perinatol. 2012;32(4):253-9,
613 doi:10.1038/jp.2011.51.
614 39. Härtel C, Pagel J, Spiegler J, Buma J, Henneke P, Zemlin M, et al. Lactobacillus
615 acidophilus/Bifidobacterium infantis probiotics are associated with increased growth of VLBWI
616 among those exposed to antibiotics. Scientific Reports. 2017;7(1), doi:10.1038/s41598-017-
617 06161-8.
618 40. Rose G. Sick individuals and sick populations. International Journal of Epidemiology.
619 1985;14:32-8, doi:10.1093/ije/30.3.427.
620 41. Zmora N, Zilberman-Schapira G, Suez J, Mor U, Dori-Bachash M, Bashiardes S, et al.
621 Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with
622 Unique Host and Microbiome Features. Cell. 2018/09/06;174(6), doi:10.1016/j.cell.2018.08.041.
623 42. Locascio RG, Desai P, Sela DA, Weimer B, Mills DA. Broad Conservation of Milk
624 Utilization Genes in *Bifidobacterium longum* subsp. *infantis* as Revealed by Comparative
625 Genomic Hybridization. Applied and Environmental Microbiology. 2010;76(22):7373-81,
626 doi:10.1128/aem.00675-10.
627 43. Duar RM, Casaburi G, Mitchell RD, Scofield LNC, Ortega Ramirez CA, Barile D, et al.
628 Comparative Genome Analysis of Bifidobacterium longum subsp. infantis Strains Reveals
629 Variation in Human Milk Oligosaccharide Utilization Genes among Commercial Probiotics.
630 Nutrients. 2020;12(11):3247, doi:10.3390/nu12113247.
631 44. National Institute of Population Research and Training (NIPORT) and ICF. Bangladesh
632 Demographic and Health Survey: Final Report. Dhaka, Bangladesh, and Rockville, Maryland,
633 USA; 2022.

634